microRNA (miRNA)

microRNA (miRNA)

Global microRNA (miRNA) Market to Reach $556.1 Million by 2027

In the changed post COVID-19 business landscape, the global market for microRNA (miRNA) estimated at US$225.5 Million in the year 2020, is projected to reach a revised size of US$556.1 Million by 2027, growing at aCAGR of 13.8% over the period 2020-2027. Products, one of the segments analyzed in the report, is projected to record 12.2% CAGR and reach US$290.1 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Services segment is readjusted to a revised 15.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $97 Million, While China is Forecast to Grow at 17.7% CAGR

The microRNA (miRNA) market in the U.S. is estimated at US$97 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$60 Million by the year 2027 trailing a CAGR of 17.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.1% and 13% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 12.5% CAGR.

Select Competitors (Total 64 Featured) -

  • Abcam Plc
  • Agilent Technologies, Inc.
  • Biodynamics Laboratory Inc.
  • BioGenex
  • Bio-Rad Laboratories Inc.
  • BioVendor — Laboratorní medicína a.s.
  • Dharmacon, a Horizon Discovery Group Co.
  • F. Hoffmann-La Roche Ltd
  • GeneCopoeia, Inc.
  • HTG Molecular Diagnostics, Inc.
  • Lexogen GmbH
  • Meridian Bioscience
  • Miltenyi Biotec
  • NanoString Technologies, Inc.
  • New England Biolabs
  • Norgen Biotek Corp
  • OriGene Technologies, Inc.
  • Promega Corporation
  • QIAGEN NV
  • Quantabio
  • SeqMatic LLC
  • Sistemic Scotland Limited
  • System Biosciences LLC
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
  • TriLink BioTechnologies Inc.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
microRNA (miRNA) – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
A Prelude to MicroRNA
Impact of Covid-19 and a Looming Global Recession
2020 Marked as a Year of Disruption & Transformation
As the Race between the Virus & Vaccines Intensifies, Where is the World Economy Headed in 2021
World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
COVID-19 Impact on mRNA Market
Global Market Prospects and Outlook
Global miRNA Market Set to Witness Rapid Growth
Disease Diagnostics Segment Leads the Market
MicroRNAs Likely to Be Instrumental in Disease Diagnosis and Treatment
Polymerase Chain Reaction (PCR) Dominates the Instruments Category
Academic and Government Research Institutes Holds the Largest Share
North America Dominates Global miRNA Market, Asia-Pacific to Witness Steady Growth
Competition
Increasing Emphasis on R&D by Players to Boost Market Growth
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increasing Incidence of Infectious Diseases and Chronic Conditions to Help miRNA Market Gallop Ahead
Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
Increasing Application in Cancer Diagnostics as Biomarkers to Drive Market Growth
Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
Breakdown of Total Number of Cancer Cases by Region: 2020
Breakdown of Total Number of Cancer Cases by Type: 2020
The Future of miRNA-based Cancer Biomarkers
Consistent Increase in Risks and Threats from Infections Drive Healthy Market Growth
Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
Infection Rates of Viruses ((per infected person)) Involved in Outbreaks Worldwide: 2020
Infectious Diseases Related Mortality High Among Children below 5 Years: Breakdown of Leading Causes of Death in Children below 5 Years (in %)
MicroRNA Biomarkers Hold Promise for Diagnosis of Infectious Diseases
Focus on Development of miRNA-based Therapeutics Bodes Well for Market Growth
Increasing Investments in miRNA to Bolster Market Growth
Diagnostics and Therapeutics Investments
Standard Methods Utilized to measure miRNA Biomarkers
Advancements in Detection Methodologies Focus on Enhancing Sensitivity and Selectivity of miRNA Detection
Increasing Demand for Liquid Biopsies to Drive the MicroRNA Market
miRNA by Type of Gastrointestinal Cancers
Circulating miRNAs as Cancer Detectors
Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for the Market
Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
Growing Global Healthcare Spending and Supportive Government Initiatives Boost Market Prospects
World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
Per Capita Healthcare Expenditure (in $) by Select Countries for 2018
miRNA and Next Generation Sequencing
Market Restraints
AN INSIGHT INTO MIRNA APPLICATIONS
CANCER
Role of miRNA in Cancer Cell
DNA Repair and Cancer
HEART DISEASE
miRNA-712
Human Homolog—microRNA-205
KIDNEY DISEASE
NERVOUS SYSTEM
Stroke
ALCOHOLISM
OBESITY
HEMOSTASIS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for microRNA (miRNA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 2: World Historic Review for microRNA (miRNA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 3: World 11-Year Perspective for microRNA (miRNA) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2016, 2021 & 2027
TABLE 4: World Recent Past, Current & Future Analysis for Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 5: World Historic Review for Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 6: World 11-Year Perspective for Products by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
TABLE 7: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 8: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 9: World 11-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
TABLE 10: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 11: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 12: World 11-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
TABLE 13: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 14: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 15: World 11-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
TABLE 16: World Recent Past, Current & Future Analysis for Immunological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 17: World Historic Review for Immunological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 18: World 11-Year Perspective for Immunological Disorders by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
TABLE 19: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 20: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 21: World 11-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
TABLE 22: World Recent Past, Current & Future Analysis for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 23: World Historic Review for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 24: World 11-Year Perspective for Neurological Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
TABLE 25: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 26: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 27: World 11-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
TABLE 28: World Recent Past, Current & Future Analysis for Academic & Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 29: World Historic Review for Academic & Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 30: World 11-Year Perspective for Academic & Government Research Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
TABLE 31: World Recent Past, Current & Future Analysis for Biotech & Pharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 32: World Historic Review for Biotech & Pharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 33: World 11-Year Perspective for Biotech & Pharma Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
TABLE 34: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 35: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 36: World 11-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
TABLE 37: USA Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 38: USA Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 39: USA 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
TABLE 40: USA Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 41: USA Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 42: USA 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
TABLE 43: USA Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 44: USA Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 45: USA 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
CANADA
TABLE 46: Canada Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 47: Canada Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 48: Canada 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
TABLE 49: Canada Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 50: Canada Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 51: Canada 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
TABLE 52: Canada Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 53: Canada Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 54: Canada 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
JAPAN
microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
TABLE 55: Japan Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 56: Japan Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 57: Japan 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
TABLE 58: Japan Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 59: Japan Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 60: Japan 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
TABLE 61: Japan Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 62: Japan Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 63: Japan 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
CHINA
microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
TABLE 64: China Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 65: China Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 66: China 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
TABLE 67: China Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 68: China Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 69: China 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
TABLE 70: China Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 71: China Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 72: China 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
EUROPE
microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
TABLE 73: Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 74: Europe Historic Review for microRNA (miRNA) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 75: Europe 11-Year Perspective for microRNA (miRNA) by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2016, 2021 & 2027
TABLE 76: Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 77: Europe Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 78: Europe 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
TABLE 79: Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 80: Europe Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 81: Europe 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
TABLE 82: Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 83: Europe Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 84: Europe 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
FRANCE
microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
TABLE 85: France Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 86: France Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 87: France 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
TABLE 88: France Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 89: France Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 90: France 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
TABLE 91: France Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 92: France Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 93: France 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
GERMANY
microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
TABLE 94: Germany Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 95: Germany Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 96: Germany 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
TABLE 97: Germany Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 98: Germany Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 99: Germany 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
TABLE 100: Germany Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 101: Germany Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 102: Germany 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
ITALY
TABLE 103: Italy Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 104: Italy Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 105: Italy 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
TABLE 106: Italy Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 107: Italy Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 108: Italy 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
TABLE 109: Italy Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 110: Italy Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 111: Italy 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
UNITED KINGDOM
microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
TABLE 112: UK Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 113: UK Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 114: UK 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
TABLE 115: UK Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 116: UK Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 117: UK 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
TABLE 118: UK Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 119: UK Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 120: UK 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
REST OF EUROPE
TABLE 121: Rest of Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 122: Rest of Europe Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 123: Rest of Europe 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
TABLE 124: Rest of Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 125: Rest of Europe Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 126: Rest of Europe 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
TABLE 127: Rest of Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 128: Rest of Europe Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 129: Rest of Europe 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
ASIA-PACIFIC
microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
TABLE 130: Asia-Pacific Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 131: Asia-Pacific Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 132: Asia-Pacific 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
TABLE 133: Asia-Pacific Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 134: Asia-Pacific Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 135: Asia-Pacific 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
TABLE 136: Asia-Pacific Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 137: Asia-Pacific Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 138: Asia-Pacific 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
REST OF WORLD
TABLE 139: Rest of World Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 140: Rest of World Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 141: Rest of World 11-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2021 & 2027
TABLE 142: Rest of World Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 143: Rest of World Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 144: Rest of World 11-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2021 & 2027
TABLE 145: Rest of World Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 146: Rest of World Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR
TABLE 147: Rest of World 11-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2021 & 2027
IV. COMPETITION
Total Companies Profiled: 64

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings